ALZpath Inc.

We are thrilled to announce that ALZpath Inc.’s innovative pTau217 antibody has been featured in The Telegraph's article as one of the “Four new medical tests that will transform the future of health.” Dr Francesca Jackson-Spence emphasizes the significance of early detection in the article, stating, “Diagnosing Alzheimer’s disease earlier is important as there are now treatments available to slow progression in the earlier stages of this disease. Early diagnosis can give patients more autonomy, involvement, and decision-making in the trajectory of their care.” The Telegraph highlights the potential of our pTau217 antibody as an innovative diagnostic tool for the early detection of Alzheimer’s disease. Alzheimer’s disease poses a profound global health challenge, and early detection is crucial for effective intervention. The ALZpath Inc. pTau217 antibody targets a tau protein phosphorylated at site 217. pTau217 shows up as soon as amyloid plaques start forming in the brain, as a neuronal reaction to the amyloid pathology, a key indicator of Alzheimer’s disease. By targeting pTau217, ALZpath offers a less invasive and more cost-effective alternative to traditional diagnostic methods such as PET imaging and lumbar punctures. Early trials with 786 participants indicate the test has high accuracy in detecting amyloid pathology in the brain, marking a significant step forward in Alzheimer’s research. This recognition highlights ALZpath’s commitment to democratize access to innovative diagnostics and accelerate the discovery of new treatments. We are optimistic about the future possibilities our pTau217 antibody offers in transforming Alzheimer’s diagnosis and patient care. Stay tuned for more updates as ALZpath continues to lead the way in enhancing Alzheimer’s detection and management. 📌 Read the full article by Dr. Francesca Jackson-Spence here: https://lnkd.in/ePzG4uKb 📌 Curious to learn more about ALZpath and our innovative solutions? Visit our website: https://alzpath.bio/ #AlzheimersAwareness #MedicalInnovation #EarlyDetection #HealthTech #ALZpath #TheTelegraph #pTau217 #Innovation

We are thrilled to announce our collaboration with Beckman Coulter Diagnostics to advance Alzheimer's disease testing. Kathleen Orland, Beckman Coulter SVP General Manager, Clinical Chemistry and Immunoassay, shared: “We selected ALZpath’s pTau217 antibody following rigorous evaluation due to its high performance in detecting amyloid pathology and ability to integrate into our advanced DxI 9500 platform to support broad-based testing. We are excited about the combination of ALZpath and Beckman Coulter innovations coming together to develop a new fully automated, high throughput, blood-based Alzheimer's disease test for the millions of patients who suffer from dementia worldwide."   This partnership represents a significant step forward in our mission to democratize access to cutting-edge diagnostic tools and improve patient care. Together, we are pushing the boundaries of innovation to bring hope to millions of individuals and families affected by Alzheimer's disease.   📌 Read the full press release here: https://lnkd.in/gbvC4p4B   #AlzheimersDisease #Diagnostics #Innovation #Healthcare #Partnership #ALZpath #BeckmanCoulter #Biotech #MedicalResearch #pTau217 

ALZpath Inc. is thrilled to announce its attendance at the Alzheimer's Association International Conference (AAIC) #AAIC2024 in Philadelphia, USA from July 28 to August 1. We are excited to share our latest advancements in Alzheimer's research and diagnostics. 📌Learn more about ALZpath at https://alzpath.bio/ Reach out to us to schedule a meeting at [email protected] #AAIC2024 #Alzheimers #HealthcareInnovation #ALZpath #Neurology #pTau217

Exciting News! The special episode of the Alzheimer's Speaks Radio podcast featuring our very own ALZpath Inc. Medical Science Liaison, Dr. Teodora Stoica, PhD, is now live! In this episode, Dr. Stoica shares her extensive knowledge on neurodegenerative disease solutions and innovations, including the use and implementation of our #ALZpathDx blood test for detecting Alzheimer’s disease pathology. This is a must-listen for clinicians seeking valuable insights and resources on advancements in Alzheimer’s detection and patient care. Listen to the podcast today on all major podcast platforms including Apple Podcasts, Spotify, or access the recording directly here: https://pod.link/986940432 We would love to hear your thoughts and follow-up questions! Please submit any comments or questions to us here: https://lnkd.in/gqFpTaGa or email us at [email protected] #Alzheimers #ALZpathDx #Podcast #Healthcare #PatientCare #MedicalScience #pTau217

"We are excited about the combination of ALZpath and Beckman Coulter innovations coming together to develop a new diagnostic assay targeting earlier and more accurate detection of Alzheimer’s disease biomarkers.” -Kathleen Orland #alzheimersdiagnosis #diagnostics #neurology #beckmancoulter

We are thrilled to share that ALZpath Inc. has signed a licensing agreement with Beckman Coulter Diagnostics to leverage our proprietary #pTau217 antibody for the development of a blood-based diagnostic test for #Alzheimer's disease. This innovative test will be run on Beckman Coulter’s state-of-the-art DxI 9500 Immunoassay Analyzer, aiming to transform Alzheimer's diagnosis globally. The ALZpath pTau217 antibody is renowned for its high performance, and integrating our antibody into a blood-based in vitro diagnostic (IVD) test on Beckman Coulter’s DxI 9500 platform, known for its precision and scalability, will significantly enhance access to early and accurate testing for Alzheimer’s disease pathology. Chad Holland, ALZpath CEO, stated, “Collaborating with Beckman Coulter will significantly expand access to precise testing and early diagnosis for patients around the world.” Kathleen Orland from Beckman Coulter added, “We are excited about the combination of ALZpath and Beckman Coulter innovations coming together to develop a new fully automated, high throughput, blood-based Alzheimer's disease test.” Stay tuned for more updates as we work together to revolutionize Alzheimer’s diagnostics! 📌 Read the full press release here: https://lnkd.in/gbvC4p4B 📌 Learn more about ALZpath here: https://alzpath.bio/ #AlzheimersDiagnosis #pTau217 #InnovativeDiagnostics #BloodTest #DxI9500 #HealthcareInnovation #EarlyDetection #Neurology #Biotech #MedicalBreakthrough #PatientCare #ClinicalResearch #PrecisionMedicine #GlobalHealth #FutureOfMedicine

We are thrilled to announce the latest publication featuring the ALZpath Inc. pTau217 assay now available in Alzheimer's & Dementia the journal of the Alzheimer's Association®. This pivotal study, led by first author Lianlian Du, highlights the significant potential of plasma #pTau217 in predicting cognitive decline and enhancing early detection of Alzheimer's disease, and suggests that using pTau217 as a screening tool could reduce the need for invasive PET scans, thereby accelerating the path to effective treatments. Lianlian Du, Sterling Johnson, and the Wisconsin Registry for Alzheimer's Prevention  team, your work significantly advances our understanding of how to leverage Alzheimer's biomarkers to predict cognitive decline and paves the way for future innovations in timely Alzheimer’s diagnosis and treatment. We are honored that our ALZpath Inc. pTau217 assay contributed to this impactful research. Congratulations to all authors on this remarkable achievement! Lianlian Du, PhD, Rebecca Langhough, PhD, Rachael E. Wilson, PhD, Ramiro Eduardo Rea Reyes, PhD, Bruce P. Hermann, PhD, Erin Jonaitis, PhD, Tobey J. Betthauser, PhD, Nathaniel A. Chin, MD, Bradley Christian, PhD, Lauren Chaby, PhD, Andreas Jeromin, PhD, Kaj Blennow, MD, PhD, Henrik Zetterberg, MD, PhD, Nicholas Ashton, PhD, Sterling C. Johnson, PhD. 📌 Read the full publication here: https://lnkd.in/gWhSSbWe 📌Learn more about ALZpath here: https://alzpath.bio/ #AlzheimersResearch #ALZpath #Biomarkers #EarlyDetection #AlzheimersDisease #AlzheimersAndDementia

ALZpath is pleased to welcome Chad Holland as our new CEO, effective immediately. We also celebrate the tremendous contributions of our co-founder and outgoing CEO Venkat Shastri. Board Chair Jerre Stead: “ALZpath is at a pivotal moment of growth. With Chad as our CEO, the support of our board and scientific advisory board, as well as continued counsel from Venkat, we will continue our successful trajectory, helping to transform the Alzheimer’s care continuum. We are excited about our success to date, and we are tremendously grateful to Venkat, who has given so much to help change #Alzheimer’s care, and whose leadership has brought our company to this point.” Read more: https://lnkd.in/g8TkBWtk

We are delighted to invite you to a special episode of Alzheimer's Speaks Radio podcast featuring ALZpath Inc. Medical Science Liaison, Dr. Teodora Stoica, PhD, featuring the use and implementation of our #ALZpathDx blood test to detect Alzheimer’s disease pathology. Dr. Stoica brings a wealth of knowledge in neurodegenerative disease solutions and innovations, and provides clinicians with valuable insights and resources to understand advancements in Alzheimer’s detection, including ALZpathDx. Tune in for an insightful discussion on the latest in Alzheimer's clinical solutions and patient care. We look forward to sharing more highlights from this conversation soon! We invite you to submit questions for the podcast discussion by July 7th: https://lnkd.in/g6SekxS4 https://lnkd.in/gGNZgW-i or email us at [email protected] Listen to the podcast on Tuesday, July 16, on all major podcast outlets including Apple Podcasts, Spotify, or access the recording directly here: https://lnkd.in/gFA_smqP #ALZpathDx #Podcast #Healthcare #PatientCare #MedicalScience #pTau217

We are thrilled to highlight an exciting study published in JAMA Neurology, showing that fragmentation in daily patterns of rest and activity may be a risk factor for amyloid pathology nearly 8 years later, especially in APOE4 carriers and across all pTau217 levels. This impactful study was led by Phuong Thuy Nguyen Ho, Sanne Hoepel, Maria Rodriguez-Ayllon, Annemarie Luik, Meike Vernooij, and Julia Neitzel, PhD, this research provides important insights into the relationship between lifestyle patterns and amyloid deposition across stages of amyloid accumulation defined by ALZpath Inc. pTau217 and Aβ42/40.    The current study was embedded in the Rotterdam Study, with an exceptional team from Erasmus University Rotterdam Medical Centre, Harvard T.H. Chan School of Public Health and Trimbos-instituut—the Netherlands Institute of Mental Health and Addiction, Utrecht, the Netherlands. We are proud our ALZpath assay contributed to this remarkable research. Let’s continue to push forward in understanding and preventing Alzheimer’s Disease!   #pTau217 #AlzheimersResearch #Neurology #MedicalResearch #SleepHealth #24HourActivityRhythms #JAMANeurology   Read more: https://lnkd.in/grjSk8YT.